Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 3 | 6 |
| List of Tables | 5 | 2 |
| List of Figures | 7 | 2 |
| Global Hospital Acquired Bacterial Infections Market - Introduction | 9 | 1 |
| GBI Research Report Guidance | 9 | 1 |
| Global Hospital Acquired Bacterial Infections Market - Market Overview | 10 | 7 |
| Introduction | 10 | 1 |
| Revenue Forecasts for the Global Hospital Acquired Bacterial Infections Market | 11 | 1 |
| Sales Value | 11 | 1 |
| Branded Vs Generics | 12 | 1 |
| Annual Cost of Therapy | 13 | 1 |
| Treatment Usage Patterns | 14 | 1 |
| Diseased Population | 15 | 1 |
| Diagnosed Population | 15 | 1 |
| Prescription Population | 15 | 1 |
| Hospital Acquired Bacterial Infections Market Drivers | 15 | 1 |
| Increase in Antibacterial Resistance due to Their Frequent Usage | 15 | 1 |
| Threat from Emergence of Superbugs | 15 | 1 |
| Hospital Acquired Bacterial Infections Market Restraints | 16 | 1 |
| Increased Penetration of Generics Pose as a Threat for Primary Manufacturers | 16 | 1 |
| Increased Anti-bacterial Surveillance in Hospitals | 16 | 1 |
| Global Hospital Acquired Bacterial Infections Market - Therapeutic Landscape | 17 | 29 |
| Hospital Acquired Urinary Tract Infections (UTI) Market | 17 | 1 |
| Introduction | 17 | 1 |
| Sales Value | 17 | 2 |
| Annual Cost of Therapy | 19 | 1 |
| Treatment Flow Algorithm | 20 | 1 |
| Treatment Usage Patterns | 21 | 1 |
| Diseased Population | 22 | 1 |
| Diagnosed Population | 22 | 1 |
| Prescription Population | 22 | 1 |
| Market Share by Geography | 23 | 1 |
| Hospital Acquired Bacterial Pneumonia (HABP) Market | 24 | 1 |
| Introduction | 24 | 1 |
| Sales Value | 25 | 1 |
| Annual Cost of Therapy | 26 | 1 |
| Treatment Flow Algorithm | 27 | 1 |
| Treatment Usage Patterns | 28 | 1 |
| Diseased Population | 29 | 1 |
| Diagnosed Population | 29 | 1 |
| Prescription Population | 29 | 1 |
| Market Share by Geography | 30 | 1 |
| Hospital Acquired Bacterial Surgical Site Infections Market | 31 | 1 |
| Introduction | 31 | 1 |
| Sales Value | 31 | 2 |
| Annual Cost of Therapy | 33 | 1 |
| Treatment Flow Algorithm | 34 | 1 |
| Treatment Usage Patterns | 35 | 1 |
| Diseased Population | 36 | 1 |
| Diagnosed Population | 36 | 1 |
| Prescription Population | 36 | 1 |
| Market Share by Geography | 37 | 2 |
| Hospital Acquired Bacterial Blood Stream Infections (BSI) Market | 39 | 1 |
| Introduction | 39 | 1 |
| Sales Value | 39 | 1 |
| Annual Cost of Therapy | 40 | 1 |
| Treatment Flow Algorithm | 41 | 1 |
| Treatment Usage Patterns | 42 | 1 |
| Diseased Population | 43 | 1 |
| Diagnosed Population | 43 | 1 |
| Prescription Population | 43 | 1 |
| Market Share by Geography | 44 | 2 |
| Global Hospital Acquired Bacterial Infections Market - Geographical Landscape | 46 | 15 |
| Geographical Break-up | 46 | 2 |
| The US | 48 | 1 |
| Sales Value | 48 | 1 |
| Annual Cost of Therapy | 49 | 1 |
| Treatment Usage Patterns | 50 | 1 |
| Diseased Population | 51 | 1 |
| Diagnosed Population | 51 | 1 |
| Prescription Population | 51 | 1 |
| Top Five Countries in Europe | 52 | 1 |
| Sales Value | 52 | 1 |
| Country Segmentation | 53 | 1 |
| Annual Cost of Therapy | 54 | 1 |
| Treatment Usage Patterns | 55 | 1 |
| Diseased Population | 56 | 1 |
| Diagnosed Population | 56 | 1 |
| Prescription Population | 56 | 1 |
| Japan | 57 | 1 |
| Sales Value | 57 | 1 |
| Annual Cost of Therapy | 58 | 1 |
| Treatment Usage Patterns | 59 | 1 |
| Diseased Population | 60 | 1 |
| Diagnosed Population | 60 | 1 |
| Prescription Population | 60 | 1 |
| Global Hospital Acquired Bacterial Infections - Pipeline Analysis | 61 | 7 |
| Pipeline Drugs by Phase of Development | 61 | 1 |
| Research and Development Pipeline | 61 | 1 |
| Phase III Pipeline Molecules | 61 | 1 |
| Phase II Pipeline Molecules | 62 | 1 |
| Phase I, Pre-Clinical and Discovery Phase Molecules | 63 | 1 |
| Profiles of Key Late Stage Drugs | 64 | 1 |
| Oritavancin | 64 | 1 |
| Overview | 64 | 1 |
| Mechanism of Action | 64 | 1 |
| Clinical Study Details | 64 | 1 |
| Torezolid | 65 | 1 |
| Overview | 65 | 1 |
| Mechanism of Action | 65 | 1 |
| Clinical Study Details | 65 | 1 |
| Ceftobiprole Medocaril | 66 | 1 |
| Overview | 66 | 1 |
| Mechanism of Action | 66 | 1 |
| Clinical Study Details | 66 | 1 |
| Omadacycline/ PTK 0796 | 66 | 1 |
| Overview | 66 | 1 |
| Mechanism of Action | 66 | 1 |
| Clinical Study Details | 67 | 1 |
| Oritavancin | 67 | 1 |
| Overview | 67 | 1 |
| Mechanism of Action | 67 | 1 |
| Clinical Study Details | 67 | 1 |
| Global Hospital Acquired Bacterial Infections Market - Competitive Landscape | 68 | 5 |
| Competitive Profiling | 68 | 1 |
| Johnson &Johnson (J&J) | 68 | 1 |
| Overview | 68 | 1 |
| Product Portfolio | 68 | 1 |
| SWOT Analysis | 69 | 1 |
| Pfizer | 69 | 1 |
| Overview | 69 | 1 |
| Product Portfolio | 69 | 1 |
| SWOT Analysis | 70 | 1 |
| Cubist Pharmaceuticals | 70 | 1 |
| Overview | 70 | 1 |
| Product Portfolio | 70 | 1 |
| SWOT Analysis | 71 | 1 |
| Bayer | 71 | 1 |
| Overview | 71 | 1 |
| Product Portfolio | 71 | 1 |
| SWOT Analysis | 72 | 1 |
| Trius Therapeutics | 72 | 1 |
| Overview | 72 | 1 |
| Tetraphase Pharmaceuticals Inc. | 72 | 1 |
| Overview | 72 | 1 |
| Global Hospital Acquired Bacterial Infections Market - Strategic Consolidations | 73 | 6 |
| Overview | 73 | 1 |
| M&A Deals by Geography | 73 | 1 |
| M&A Deals by Value | 74 | 1 |
| M&A Deals by Deal Type | 75 | 1 |
| Merck Completes Acquisition Of Inspire Pharmaceuticals | 75 | 1 |
| SciClone Pharmaceuticals Acquires NovaMed Pharmaceuticals | 76 | 1 |
| AstraZeneca Completed the Acquisition of Novexel SA in March 2010 | 76 | 1 |
| R&D Licensing Agreements | 76 | 1 |
| Major Licensing Agreements | 77 | 1 |
| Trius Therapeutics Enters into Licensing Agreement with Bayer HealthCare for Torezolid Phosphate | 77 | 1 |
| Furiex Pharmaceuticals Enters Into Licensing Agreement with Janssen Pharmaceutica for JNJ-Q2 | 77 | 1 |
| AMRI Enters Into Licensing Agreement with Genentech | 78 | 1 |
| Optimer Pharmaceuticals Enters into Licensing Agreement with Astellas Pharma Europe for Fidaxomicin | 78 | 1 |
| Anacor Pharmaceuticals Enters Into Licensing Agreement with GlaxoSmithKline in July 2010 | 78 | 1 |
| Global Hospital Acquired Bacterial Infections Market - Appendix | 79 | 8 |
| Market Definitions | 79 | 1 |
| Abbreviations | 79 | 1 |
| Research Methodology | 80 | 6 |
| Coverage | 80 | 1 |
| Secondary Research | 80 | 1 |
| Primary Research | 81 | 1 |
| Therapeutic Landscape | 81 | 1 |
| Epidemiology-Based Forecasting | 82 | 2 |
| Market Size by Geography | 84 | 1 |
| Geographical Landscape | 85 | 1 |
| Pipeline Analysis | 85 | 1 |
| Competitive Landscape | 85 | 1 |
| Expert Panel Validation | 85 | 1 |
| Contact Us | 85 | 1 |
| Disclaimer | 85 | 1 |
| Sources | 86 | 1 |